Items where authors include "Birtle, A."
Article
Huddart, R., Hafeez, S., Omar, A. et al. (25 more authors) (2023) Acute Toxicity of Hypofractionated and Conventionally Fractionated (Chemo)Radiotherapy Regimens for Bladder Cancer: An Exploratory Analysis from the RAIDER Trial. Clinical Oncology, 35 (9). pp. 586-597. ISSN 0936-6555
Parker, C.C., James, N.D. orcid.org/0000-0002-7314-8204, Brawley, C.D. orcid.org/0000-0003-3641-278X et al. (43 more authors) (2022) Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial. PLOS Medicine, 19 (6). e1003998. ISSN 1549-1277
Crabb, S.J., Danson, S. orcid.org/0000-0002-3593-2890, Catto, J.W.F. orcid.org/0000-0003-2787-8828 et al. (16 more authors) (2021) Phase I trial of DNA methyltransferase inhibitor guadecitabine combined with cisplatin and gemcitabine for solid malignancies including urothelial carcinoma (SPIRE). Clinical Cancer Research, 27 (7). pp. 1882-1892. ISSN 1078-0432
Fulton, B., Jones, R., Powles, T. et al. (8 more authors) (2020) ATLANTIS: a randomised multi-arm phase II biomarker-directed umbrella screening trial of maintenance targeted therapy after chemotherapy in patients with advanced or metastatic urothelial cancer. Trials, 21. 344. ISSN 1745-6215
Birtle, A., Johnson, M., Chester, J. et al. (21 more authors) (2020) Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. The Lancet, 395 (10232). pp. 1268-1277. ISSN 0140-6736
Clarke, N.W., Ali, A., Ingleby, F.C. et al. (47 more authors) (2019) Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer : long-term survival results from the STAMPEDE trial. Annals of Oncology. 396. pp. 1-12. ISSN 0923-7534
James, N., Pirrie, S., Pope, A. et al. (17 more authors) (2016) TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer. Health Technology Assessment, 20. 53. ISSN 1366-5278
Andronis, L., Goranitis, I., Pirrie, S. et al. (19 more authors) (2016) Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747). BJU International. ISSN 1464-4096
James, N.D., Pirrie, S.J., Pope, A.M. et al. (19 more authors) (2016) Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both. JAMA Oncology, 2 (4). p. 493. ISSN 2374-2437
Proceedings Paper
Huddart, R., Birtle, A., Cheung, K.C. et al. (19 more authors) (2023) Randomised phase II trial of adaptive image guided bladder radiotherapy: Disease control data. In: Radiotherapy & Oncology. ESTRO 2023, 13-16 May 2023, Vienna, Austria. Elsevier , S704-S705.
Huddart, R., Birtle, A., Cheung, K.C. et al. (19 more authors) (2023) Randomised phase II trial of adaptive image guided bladder radiotherapy: patient reported outcomes. In: Radiotherapy & Oncology. ESTRO 2023, 13-16 May 2023, Vienna, Austria. Elsevier , S331-S332.